Non-hodgkin Lymphoma Developing After Discontinuation of Direct-acting Antiviral Treatment for Hepatitis C: A Case Report
Journal Title: Viral Hepatitis Journal - Year 2019, Vol 25, Issue 1
Abstract
Today, direct-acting antivirals (DAA) are the main treatment options for hepatitis C infection. However, whether malignancy risk is increased after DAA treatment is a matter of debate. Conflicting results have been reported in the relevant studies. In this paper, we present the case of B-cell non-Hodgkin lymphoma developing after DAA treatment in a patient with complete response to hepatitis C treatment.
Authors and Affiliations
Oğuz Karabay, Ertuğrul Güçlü, Tuba Hacıbekiroğlu, Mustafa Kösem
Keywords
Related Articles
- EP ID EP551635
- DOI 10.4274/vhd.galenos.2018.0029
- Views 57
- Downloads 0
Evaluation of the Seroprevalence of Hepatit A and Vaccination Status in Children Aged Two and Sixteen Years
Objective: In this study; the aim was to evaluate the seroprevalence of hepatitis A virus (HAV) in 2-16 year age group, and the rate of hepatitis A vaccination. Materials and Methods: This study was conducted on 400 chil...
An Important Financial Burden: Unnecessary Test Requests for Viral Hepatitis
Editorial
A Review of Hepatitis C in the General Population in Pakistan
To perform a systematic review of the recent scientific literature on hepatitis C infection (2010-2016) for epidemiology, genotypes, co-infection, risk factors and management regime in Pakistan. Present integrated, analy...
Real-life Outcomes of Tenofovir Disoproxil Fumarate Monotherapy in Nucleos(t)ide Analogue-naive and Nucleos(t)ide Analogue-experienced Chronic Hepatitis B Patients: A Single-center Experience
Objective: The aim of the study was to evaluate the long-term results of treatment efficacy and safety in nucleos(t)ide analogue-naive (NA-naive) and NA-experienced chronic hepatitis B (CHB) patients receiving tenofovir...
Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha
Objectives: It was aimed to evaluate health-related quality of life of patients with non-cirrhotic chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during interferon therapy with the standard short form-36 (SF-36)...